Xin Qi
Xin Qi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Tingmiao Li
Department of Clinical Laboratory, China-Japan Union Hospital of Jilin University, Changchun, China
2 shared publicationsAiwei Wang
Proteomics Research Center, Core Facility of Instruments, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking, Union Medical College, Beijing, China
1 shared publicationBinbin Zhang
Department of Pharmacy, No.79 Army Group Hospital of People’s Liberation Army Ground Force, Liaoyang, China
1 shared publication- Cancan Cui
China-Japan Union Hospital of Jilin University, Jilin University, Changchun, Jilin, China
1 shared publication - Chengyan He
Department of Laboratory Medicine, China-Japan Union Hospital of Jilin University, Changchun, China
1 shared publication Fei Xue
Department of Clinical Laboratory, China-Japan Union Hospital of Jilin University, Changchun, China
1 shared publication
Latest Publications
- 22 October 2025
- Published by Springer Nature in Metabolomics
- Vol. 21 (6) , 1-13
Investigating stage-specific metabolic alterations in colorectal cancer through urine metabolomics
Background Colorectal cancer (CRC) ranks as the third most prevalent malignancy globally, presenting a formidable early diagnostic challenge. An effective biomarker with high sensitivity and specificity can help diagnose CRC and improve the chances of successful treatment. Methods 100 healthy controls and 95 CRC patients (25 Stage 0/I, 30 stage II and 40 stage III based on Clinical stages) were recruited. Subsequently, 195 urine samples were subjected to UPLC-MS analysis. Comparative analysis was employed to elucidate noteworthy metabolic variances, and pathway analysis was conducted to unveil perturbed metabolic functions. Ultimately, metabolic panels for CRC diagnosis were constructed. Result A total of 82 metabolites exhibited statistical significance between CRC patients and healthy controls. Moreover, pathway analysis revealed that they were associated with Steroid hormone biosynthesis, Nitrogen metabolism, and D-Glutamine and D-glutamate metabolism. A composite panel consisting of Retinol, L-β-aspartyl-L-glycine, and 21-Deoxycortisol showed AUCs of 0.933/0.93 in the discovery/validation group. The panel also showed commendable efficacy across different CRC stages when these stages were compared with the healthy group,with an AUC of 0.918 for stages 0/I, 0.862 for stage II, and 0.845 for stage III. Conclusions Urine metabolome could distinguish CRC from healthy controls and reflect the changes in different stages of CRC. Potential biomarkers might be developed by targeted metabolomic analysis.
- 22 October 2025
- Published by Springer Nature in Metabolomics
- Vol. 21 (6) , 1-13
Investigating stage-specific metabolic alterations in colorectal cancer through urine metabolomics
Background Colorectal cancer (CRC) ranks as the third most prevalent malignancy globally, presenting a formidable early diagnostic challenge. An effective biomarker with high sensitivity and specificity can help diagnose CRC and improve the chances of successful treatment. Methods 100 healthy controls and 95 CRC patients (25 Stage 0/I, 30 stage II and 40 stage III based on Clinical stages) were recruited. Subsequently, 195 urine samples were subjected to UPLC-MS analysis. Comparative analysis was employed to elucidate noteworthy metabolic variances, and pathway analysis was conducted to unveil perturbed metabolic functions. Ultimately, metabolic panels for CRC diagnosis were constructed. Result A total of 82 metabolites exhibited statistical significance between CRC patients and healthy controls. Moreover, pathway analysis revealed that they were associated with Steroid hormone biosynthesis, Nitrogen metabolism, and D-Glutamine and D-glutamate metabolism. A composite panel consisting of Retinol, L-β-aspartyl-L-glycine, and 21-Deoxycortisol showed AUCs of 0.933/0.93 in the discovery/validation group. The panel also showed commendable efficacy across different CRC stages when these stages were compared with the healthy group,with an AUC of 0.918 for stages 0/I, 0.862 for stage II, and 0.845 for stage III. Conclusions Urine metabolome could distinguish CRC from healthy controls and reflect the changes in different stages of CRC. Potential biomarkers might be developed by targeted metabolomic analysis.
- Open Access
- 1 April 2025
- Published by AME Publishing Company in Cardiovascular Diagnosis and Therapy
- Vol. 15 (2) , 480-499
Recent progress in metabolomic analysis of acute coronary syndrome: a narrative review
Background and Objective: Acute coronary syndrome (ACS) is a common cardiovascular disease in clinical practice. It is caused mainly by vulnerable plaque rupture (PR) or surface plaque erosion (PE) caused by serious thrombotic events, and eventually leads to myocardial blood supply insufficiency or necrosis. The disease has high morbidity and mortality rates. In this study, we review the literature on biomarkers of ACS metabolites and modification of disease by altering related metabolic pathways through drugs, aiming to provide clarity on potential biomarkers of disease identified to date. Methods: PubMed was used for literature review. From January 1, 2014 to December 3, 2024, English articles on clinical trials, randomized controlled trials of metabolomics studies in ACS were included. Key Content and Findings: In this review, we discuss the advantages and disadvantages of three techniques currently used for metabolomic analysis. In addition, the recent decade of metabolomic approaches to the discovery of potential diagnostic and prognostic biomarkers for ACS is reviewed. It was found that the metabolites changed in patients with ACS were mostly amino acids, lipids and carbohydrates. Tryptophan and glutamine can be used as potential diagnostic biomarkers. Mannitol and ceramide can be used as prognostic biomarkers. Drugs can improve disease by affecting changes in metabolites in the body. Conclusions: ACS studies based on metabolomics have demonstrated great potential for identifying disease-related metabolomic features in the discovery of potential biomarkers for diagnosis and prognosis and mechanisms of drug therapy.
- 1 April 2025
- Published by AME Publishing Company in Cardiovascular Diagnosis and Therapy
- Vol. 15 (2) , 480-499
Open AccessRecent progress in metabolomic analysis of acute coronary syndrome: a narrative review
Background and Objective: Acute coronary syndrome (ACS) is a common cardiovascular disease in clinical practice. It is caused mainly by vulnerable plaque rupture (PR) or surface plaque erosion (PE) caused by serious thrombotic events, and eventually leads to myocardial blood supply insufficiency or necrosis. The disease has high morbidity and mortality rates. In this study, we review the literature on biomarkers of ACS metabolites and modification of disease by altering related metabolic pathways through drugs, aiming to provide clarity on potential biomarkers of disease identified to date. Methods: PubMed was used for literature review. From January 1, 2014 to December 3, 2024, English articles on clinical trials, randomized controlled trials of metabolomics studies in ACS were included. Key Content and Findings: In this review, we discuss the advantages and disadvantages of three techniques currently used for metabolomic analysis. In addition, the recent decade of metabolomic approaches to the discovery of potential diagnostic and prognostic biomarkers for ACS is reviewed. It was found that the metabolites changed in patients with ACS were mostly amino acids, lipids and carbohydrates. Tryptophan and glutamine can be used as potential diagnostic biomarkers. Mannitol and ceramide can be used as prognostic biomarkers. Drugs can improve disease by affecting changes in metabolites in the body. Conclusions: ACS studies based on metabolomics have demonstrated great potential for identifying disease-related metabolomic features in the discovery of potential biomarkers for diagnosis and prognosis and mechanisms of drug therapy.
- Open Access
- 23 November 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1243673
Association of baseline and dynamic arterial stiffness status with dyslipidemia: a cohort study
Background and aims: Dyslipidemia is known to contribute to arterial stiffness, while the inverse association remains unknown. This study aimed to explore the association of baseline arterial stiffness and its changes, as determined by brachial-ankle pulse wave velocity (baPWV), with dyslipidemia onset in the general population.Methods: This study enrolled participants from Beijing Health Management Cohort using measurements of the first visit from 2012 to 2013 as baseline, and followed until the dyslipidemia onset or the end of 2019. Unadjusted and adjusted Cox proportional regression models were used to evaluate the associations of baseline baPWV and baPWV transition (persistent low, onset, remitted and persistent high) with incident dyslipidemia.Results: Of 4362 individuals (mean age: 55.5 years), 1490 (34.2%) developed dyslipidemia during a median follow-up of 5.9 years. After adjusting for potential confounders, participants with elevated arterial stiffness at baseline had an increased risk of dyslipidemia (HR, 1.194; 95% CI, 1.050-1.358). Compared with persistent low baPWV, new-onset and persistent high baPWV were associated with a 51.2% and 37.1% excess risk of dyslipidemia.Conclusion: The findings indicated that arterial stiffness is an early risk factor of dyslipidemia, suggesting a bidirectional association between arterial stiffness and lipid metabolism.
- 23 November 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1243673
Open AccessAssociation of baseline and dynamic arterial stiffness status with dyslipidemia: a cohort study
Background and aims: Dyslipidemia is known to contribute to arterial stiffness, while the inverse association remains unknown. This study aimed to explore the association of baseline arterial stiffness and its changes, as determined by brachial-ankle pulse wave velocity (baPWV), with dyslipidemia onset in the general population.Methods: This study enrolled participants from Beijing Health Management Cohort using measurements of the first visit from 2012 to 2013 as baseline, and followed until the dyslipidemia onset or the end of 2019. Unadjusted and adjusted Cox proportional regression models were used to evaluate the associations of baseline baPWV and baPWV transition (persistent low, onset, remitted and persistent high) with incident dyslipidemia.Results: Of 4362 individuals (mean age: 55.5 years), 1490 (34.2%) developed dyslipidemia during a median follow-up of 5.9 years. After adjusting for potential confounders, participants with elevated arterial stiffness at baseline had an increased risk of dyslipidemia (HR, 1.194; 95% CI, 1.050-1.358). Compared with persistent low baPWV, new-onset and persistent high baPWV were associated with a 51.2% and 37.1% excess risk of dyslipidemia.Conclusion: The findings indicated that arterial stiffness is an early risk factor of dyslipidemia, suggesting a bidirectional association between arterial stiffness and lipid metabolism.